Carregant...
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Inhibiting the programmed cell death ligand-1 (PD-L1)/programmed cell death receptor-1 (PD-1) signaling axis reinvigorates the antitumor immune response with remarkable clinical efficacy. Yet, low response rates limit the benefits of immunotherapy to a minority of patients. Recent studies have explo...
Guardat en:
| Publicat a: | J Immunol Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Hindawi
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7886511/ https://ncbi.nlm.nih.gov/pubmed/33628854 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2021/8839978 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|